DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/scd628/vicals) has announced the addition of the "Vical's Allovectin - Advancing immunotherapy for metastatic melanoma" report to their offering.
Metastatic melanoma, long an underserved indication, has seen two new products approved in recent months: BMS' Yervoy and Roche's Zelboraf. A third product, Vical's Allovectin-7, is nearing the end of phase III testing, with top line results anticipated in Q2 2012. Ten years ago, Allovectin-7 was in a similar position, but it failed to meet its efficacy endpoint in phase III. Since then, Vical increased the dose and made several changes to clinical trial design that should give Allovectin-7 an edge. Will these changes be sufficient for Allovectin-7 to succeed this time around? This report reviews the evidence for and against Allovectin-7, the odds for success in phase III, potential regulatory risks, and the commercial opportunity in metastatic melanoma for another immunotherapy.
Key Topics Covered:
INTRODUCTION AND BACKGROUND
1. Metastatic melanoma - aggressive and difficult to treat
2. A small but valuable market
3. The melanoma treatment landscape is undergoing rapid change
ALLOVECTINS CLINICAL DEVELOPMENT
1. Vical returns with a higher dose of Allovectin
2. Vical's high dose phase III trial
- Phase III trial design enhancements
3. Phase III is proceeding, but the event rate has lagged behind expectations
1. Does the mechanism make sense in melanoma?
2. The risks of cancer immunotherapy
3. Will Allovectin succeed in the pivotal phase III trial?
4. There could be regulatory risk ahead
5. Usage will have many restrictions with commercial implications
1. Revenue projections
2. Potential competition
- Avax Technologies
- AB Science
- Bristol Myers Squibb
For more information visit http://www.researchandmarkets.com/research/scd628/vicals
Source: Research and Markets